Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD: Valacyclovir, Celecoxib, and Paxlovid in Long COVID
NCT07597902Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Oct 2026
- Primary completion
- Jun 2028
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of valaciclovir, celecoxib oral solution and Nirmatrelvir in post-COVID-19 condition (PCC) (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: EuroQol Five-Dimensional Health Questionnaire Visual Analogue Scale at 20 weeks. Started Oct 2026; status: recruiting.
02
Drugs
valaciclovircelecoxib oral solutionNirmatrelvir
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT07597902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07597902.